Ted M. Ross

Enhancement of antibodies to the human immunodeficiency virus type 1 envelope by using the molecular adjuvant C3d.

Induction of heterosubtypic immunity to influenza A virus using a DNA vaccine expressing hemagglutinin-C3d fusion proteins.

Impact of glycosylation on the immunogenicity of a DNA-based influenza H5 HA vaccine.

Particle-based vaccines for HIV-1 infection.

Protection against influenza virus infection by intranasal administration of C3d-fused hemagglutinin.

Generation and characterization of the humoral immune response to DNA immunization with a chimeric beta-amyloid-interleukin-4 minigene.

Independent but not synergistic enhancement to the immunogenicity of DNA vaccine expressing HIV-1 gp120 glycoprotein by codon optimization and C3d fusion in a mouse model.

Mouse strain-dependent differences in enhancement of immune responses by C3d.

Elicitation of neutralizing antibodies with DNA vaccines expressing soluble stabilized human immunodeficiency virus type 1 envelope glycoprotein trimers conjugated to C3d.

Cutting edge: C3d functions as a molecular adjuvant in the absence of CD21/35 expression.

Characterization of a DNA vaccine expressing a human immunodeficiency virus-like particle.

DNA vaccines expressing soluble CD4-envelope proteins fused to C3d elicit cross-reactive neutralizing antibodies to HIV-1.

Multiple residues in the extracellular domains of CCR3 are critical for coreceptor activity.

Unique V3 loop sequence derived from the R2 strain of HIV-type 1 elicits broad neutralizing antibodies.

C3d enhances immune responses using low doses of DNA expressing the HIV-1 envelope from codon-optimized gene sequences.

Elicitation of immunity to HIV type 1 Gag is determined by Gag structure.

HIV-1 Envgp140 trimers elicit neutralizing antibodies without efficient induction of conformational antibodies.

A minimum CR2 binding domain of C3d enhances immunity following vaccination.

Virus-like particles: designing an effective AIDS vaccine.

Membrane embedded HIV-1 envelope on the surface of a virus-like particle elicits broader immune responses than soluble envelopes.

Lentivirus-like particles without reverse transcriptase elicit efficient immune responses.

Influenza virus-like particles elicit broader immune responses than whole virion inactivated influenza virus or recombinant hemagglutinin.

Complement-mediated activation of the adaptive immune responses: role of C3d in linking the innate and adaptive immunity.

Reduction of anti-HIV-1 Gag immune responses during co-immunization: immune interference by the HIV-1 envelope.

Developing broadly reactive HIV-1/AIDS vaccines: a review of polyvalent and centralized HIV-1 vaccines.

Mucosal vaccine vectors: replication-competent versus replication-deficient poxviruses.

Immunostimulant adjuvant patch enhances humoral and cellular immune responses to DNA immunization.

Antibody neutralization.

Cross-clade protective immune responses to influenza viruses with H5N1 HA and NA elicited by an influenza virus-like particle.

HIV genes diversify in B cells.

A bivalent influenza VLP vaccine confers complete inhibition of virus replication in lungs.

H5N1 VLP vaccine induced protection in ferrets against lethal challenge with highly pathogenic H5N1 influenza viruses.

DNA epitope vaccine containing complement component C3d enhances anti-amyloid-beta antibody production and polarizes the immune response towards a Th2 phenotype.

Elicitation of protective immune responses using a bivalent H5N1 VLP vaccine.

Viral sequence diversity: challenges for AIDS vaccine designs.

Simian immunodeficiency virus pathogenesis.

The role of RNA folding free energy in the evolution of the polymerase genes of the influenza A virus.

Human immunodeficiency virus-like particles with consensus envelopes elicited broader cell-mediated peripheral and mucosal immune responses than polyvalent and monovalent Env vaccines.

A trivalent virus-like particle vaccine elicits protective immune responses against seasonal influenza strains in mice and ferrets.

Critical role of IL-17RA in immunopathology of influenza infection.

Impaired immune responses in the lungs of aged mice following influenza infection.

C3d adjuvant activity is reduced by altering residues involved in the electronegative binding of C3d to CR2.

Animal lentiviruses. Editorial.

Modeling host responses in ferrets during A/California/07/2009 influenza infection.

Enhancement of anti-DIII antibodies by the C3d derivative P28 results in lower viral titers and augments protection in mice.

West Nile virus.

Dengue virus.

Vaccination with DNA plasmids expressing Gn coupled to C3d or alphavirus replicons expressing gn protects mice against Rift Valley fever virus.

Properly folded bacterially expressed H1N1 hemagglutinin globular head and ectodomain vaccines protect ferrets against H1N1 pandemic influenza virus.

Seroprevalence following the second wave of Pandemic 2009 H1N1 influenza in Pittsburgh, PA, USA.

Hemagglutinin displayed baculovirus protects against highly pathogenic influenza.

Bacterial HA1 vaccine against pandemic H5N1 influenza virus: evidence of oligomerization, hemagglutination, and cross-protective immunity in ferrets.

Vaccination of patients with mild and severe asthma with a 2009 pandemic H1N1 influenza virus vaccine.

Challenges in improving influenza vaccine protection in the elderly.

A computationally optimized broadly reactive antigen (COBRA) based H5N1 VLP vaccine elicits broadly reactive antibodies in mice and ferrets.

An agent-based model of inflammation and fibrosis following particulate exposure in the lung.

Acute murine H5N1 influenza A encephalitis.

Large scale comparison of innate responses to viral and bacterial pathogens in mouse and macaque.

Baculovirus-produced influenza virus-like particles in mammalian cells protect mice from lethal influenza challenge.

Adjuvants that stimulate TLR3 or NLPR3 pathways enhance the efficiency of influenza virus-like particle vaccines in aged mice.

Prevalence of antibodies against seasonal influenza A and B viruses during the 2009-2010 and 2010-2011 influenza seasons in residents of Pittsburgh, PA, USA.

Animal models of Rift Valley fever virus infection.

Absence of fetal transmission of H1N1 despite severe maternal infection.

Elicitation of anti-1918 influenza virus immunity early in life prevents morbidity and lower levels of lung infection by 2009 pandemic H1N1 influenza virus in aged mice.

Antibody breadth and protective efficacy are increased by vaccination with computationally optimized hemagglutinin but not with polyvalent hemagglutinin-based H5N1 virus-like particle vaccines.

Evaluation of heterologous vaginal SHIV SF162p4 infection following vaccination with a polyvalent Clade B virus-like particle vaccine.

Influenza virus H1N1pdm09 infections in the young and old: evidence of greater antibody diversity and affinity for the hemagglutinin globular head domain (HA1 Domain) in the elderly than in young adults and children.

Computationally optimized antigens to overcome influenza viral diversity.

Plasmacytoid dendritic cell depletion leads to an enhanced mononuclear phagocyte response in lungs of mice with lethal influenza virus infection.

A computationally optimized hemagglutinin virus-like particle vaccine elicits broadly reactive antibodies that protect nonhuman primates from H5N1 infection.

Complex patterns of human antisera reactivity to novel 2009 H1N1 and historical H1N1 influenza strains.

Oligomeric recombinant H5 HA1 vaccine produced in bacteria protects ferrets from homologous and heterologous wild-type H5N1 influenza challenge and controls viral loads better than subunit H5N1 vaccine by eliciting high-affinity antibodies.

Sequential seasonal H1N1 influenza virus infections protect ferrets against novel 2009 H1N1 influenza virus.

Sequencing, annotation, and characterization of the influenza ferret infectome.

Rhesus macaques vaccinated with consensus envelopes elicit partially protective immune responses against SHIV SF162p4 challenge.

Intranasal antibody gene transfer in mice and ferrets elicits broad protection against pandemic influenza.

Immune history shapes specificity of pandemic H1N1 influenza antibody responses.

Immunization with cross-conserved H1N1 influenza CD4+ T-cell epitopes lowers viral burden in HLA DR3 transgenic mice.

Mucosal pre-exposure to Th17-inducing adjuvants exacerbates pathology after influenza infection.

A novel nonhuman primate model for influenza transmission.

A novel outbred mouse model of 2009 pandemic influenza and bacterial co-infection severity.

H1N1, but not H3N2, influenza A virus infection protects ferrets from H5N1 encephalitis.

Massive mobilization of dendritic cells during influenza A virus subtype H5N1 infection of nonhuman primates.

Effects of aging on influenza virus infection dynamics.

Cross-conservation of T-cell epitopes: now even more relevant to (H7N9) influenza vaccine design.

Influence of pre-existing hemagglutination inhibition titers against historical influenza strains on antibody response to inactivated trivalent influenza vaccine in adults 50-80 years of age.

Eliciting broadly protective antibody responses against influenza.

Influenza virus infection elicits protective antibodies and T cells specific for host cell antigens also expressed as tumor-associated antigens: a new view of cancer immunosurveillance.

Use of transmission electron microscopy to identify nanocrystals of challenging protein targets.

A polyvalent Clade B virus-like particle HIV vaccine combined with partially protective oral preexposure prophylaxis prevents simian-human immunodeficiency virus Infection in macaques and primes for virus-amplified immunity.

Challenges and future in vaccines, drug development, and immunomodulatory therapy.

H5 N-terminal β sheet promotes oligomerization of H7-HA1 that induces better antibody affinity maturation and enhanced protection against H7N7 and H7N9 viruses compared to inactivated influenza vaccine.

Potential antigenic explanation for atypical H1N1 infections among middle-aged adults during the 2013-2014 influenza season.

C3d adjuvant effects are mediated through the activation of C3d-specific autoreactive T cells.

Cross-protection against H7N9 influenza strains using a live-attenuated H7N3 virus vaccine.

Randomized, controlled trial of high-dose influenza vaccine among frail residents of long-term care facilities.

Cocktail of H5N1 COBRA HA vaccines elicit protective antibodies against H5N1 viruses from multiple clades.

The inflammatory response to influenza A virus (H1N1): An experimental and mathematical study.

Identification of Hemagglutinin Residues Responsible for H3N2 Antigenic Drift during the 2014-2015 Influenza Season.

Enhanced Influenza Virus-Like Particle Vaccination with a Structurally Optimized RIG-I Agonist as Adjuvant.

Emerging Infections of CNS: Avian Influenza A Virus, Rift Valley Fever Virus and Human Parechovirus.

Portrait of Dr. Ted M. Ross.

Sequential Infection in Ferrets with Antigenically Distinct Seasonal H1N1 Influenza Viruses Boosts Hemagglutinin Stalk-Specific Antibodies.

Use of computational and recombinant technologies for developing novel influenza vaccines.

Are plasma mineral levels related to antibody response to influenza vaccination in older adults?

Design and Characterization of a Computationally Optimized Broadly Reactive Hemagglutinin Vaccine for H1N1 Influenza Viruses.

Delta inulin-derived adjuvants that elicit Th1 phenotype following vaccination reduces respiratory syncytial virus lung titers without a reduction in lung immunopathology.